Phase III colorectal trial a landmark for Alchemia's lead cancer product
This article was originally published in Scrip
Executive Summary
Alchemia's oncology business has reached a milestone with the start of a multinational Phase III trial for its lead drug candidate, an irinotecan product based on the Australian firm's proprietary HyACT formulation platform.